6.99

0.00% 0.00

Relmada Therapeutics Inc (RLMD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$6.99

Offen:

$6.88

24-Stunden-Volumen:

575.04K

Relative Volume:

0.38

Marktkapitalisierung:

$726.89M

Einnahmen:

Nettoeinkommen (Verlust:

$-57.39M

KGV:

-4.7557

EPS:

-1.4698

Netto-Cashflow:

$-45.79M

1W Leistung:

+9.56%

1M Leistung:

+57.08%

6M Leistung:

+236.06%

1J Leistung:

+2,466%

1-Tages-Spanne:

$6.81

$7.095

1-Wochen-Bereich:

$6.375

$7.37

52-Wochen-Spanne:

$0.243

$7.51

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Firmenname

Relmada Therapeutics Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

646 876 3459

Adresse

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Mitarbeiter

Twitter

@relmada

Nächster Verdiensttermin

2026-03-19

Neueste SEC-Einreichungen

RLMD's Discussions on Twitter

Compare RLMD vs MOBBW, GOODO, PSNYW, SHMD, DWLD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLMD	3.03	0	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	2.30	2.52B	0	0	0	0.00
GOODO Gladstone Commercial Corporation	19.60	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	3.99	364.47M	2.07B	-1.42B	-1.37B	-0.6765
SHMD Schmid Group N V	5.155	297.48M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	44.04	0	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-24	Eingeleitet	Piper Sandler	Overweight
2026-01-23	Fortgesetzt	Leerink Partners	Outperform
2025-12-22	Eingeleitet	Jefferies	Buy
2025-11-19	Hochstufung	Mizuho	Neutral → Outperform
2024-12-05	Herabstufung	Mizuho	Outperform → Neutral
2024-09-17	Hochstufung	Jefferies	Hold → Buy
2024-06-05	Herabstufung	Goldman	Neutral → Sell
2022-10-14	Herabstufung	Goldman	Buy → Neutral
2022-10-14	Herabstufung	Guggenheim	Buy → Neutral
2022-10-14	Herabstufung	Truist	Buy → Hold
2022-10-13	Herabstufung	Oppenheimer	Outperform → Perform
2021-11-18	Eingeleitet	Mizuho	Buy
2021-05-20	Fortgesetzt	Goldman	Buy
2020-10-28	Herabstufung	Goldman	Buy → Neutral
2020-07-14	Eingeleitet	Oppenheimer	Outperform
2020-05-04	Eingeleitet	SunTrust	Buy
2020-04-21	Eingeleitet	Goldman	Buy
2020-01-27	Eingeleitet	Jefferies	Buy
2020-01-10	Eingeleitet	SVB Leerink	Outperform
2019-12-16	Eingeleitet	Guggenheim	Buy

Alle ansehen

Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten

12:49 PM

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research

12:49 PM

12:46 PM

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

12:46 PM

Apr 04, 2026

RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

RLMD PE Ratio & Valuation, Is RLMD Overvalued - intellectia.ai

Apr 04, 2026

Apr 03, 2026

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan

Apr 03, 2026

Apr 02, 2026

Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK

Apr 02, 2026

Mar 31, 2026

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN

Mar 31, 2026

Mar 30, 2026

Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN

Mar 30, 2026

Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha

Mar 30, 2026

With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan

Mar 30, 2026

Mar 29, 2026

Relmada wins bullish view at Piper Sandler on cancer therapy - MSN

Mar 29, 2026

Mar 28, 2026

Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - msn.com

Mar 28, 2026

Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN

Mar 28, 2026

Mar 27, 2026

Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com

Mar 26, 2026

Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget

Mar 26, 2026

Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com

Mar 25, 2026

RLMD stock surges 42% in a week: Here's what you should know - MSN

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com Canada

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com

Mar 25, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat

Mar 25, 2026

Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN

Mar 25, 2026

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey

Mar 25, 2026

Mar 24, 2026

Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - gurufocus.com

Mar 24, 2026

Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha

Mar 24, 2026

Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo

Mar 24, 2026

Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat

Mar 24, 2026

Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus

Mar 24, 2026

Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com

Mar 24, 2026

Mar 22, 2026

Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart

Mar 21, 2026

Mar 20, 2026

Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks

Mar 20, 2026

Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks

Mar 20, 2026

Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com

Mar 20, 2026

Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 20, 2026